The FDA Approved a Higher Dose of Wegovy. Here Is What That Means for Your Coverage.

4 minute read

The Food and Drug Administration approved a new higher-dose formulation of Wegovy on March 19, 2026. The new dose, 7.2 mg of semaglutide injection, will be marketed as Wegovy HD. The approval came 54 days after filing, under the FDA's Commissioner's National Priority Voucher program, which grants accelerated review to applications addressing national health priorities.¹

If you currently take Wegovy, or if you have been trying to get coverage for it, this approval changes several things worth knowing about.

What Was Approved

Wegovy HD is an injectable semaglutide at a dose of 7.2 mg, compared to the 2.4 mg maximum dose that has been the standard for the branded Wegovy injection since its original approval. The new dose is indicated for adults with obesity or overweight with at least one weight-related condition, the same population covered under the existing approval.¹

Clinical data showed that the higher dose produced additional average weight reduction compared to the previously approved doses. In people with both obesity and type 2 diabetes, the higher dosage delivered comparable blood sugar lowering to the lower doses.¹

The most common side effects are consistent with what semaglutide users already know: nausea, vomiting, diarrhea, constipation, and abdominal pain. The FDA noted one new finding at the higher dose, reports of altered skin sensation described as sensitivity, pain, or burning, which occurred more frequently with the 7.2 mg dose than with lower doses and generally resolved on its own or with dose reduction. The FDA is continuing to investigate this finding.¹

Wegovy HD carries the same boxed warning as existing Wegovy regarding a potential risk of thyroid C-cell tumors observed in rodent studies, and it is not appropriate for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2.¹

What This Means If You Are Already on Wegovy

If you are currently on the 2.4 mg dose of Wegovy and your physician believes you would benefit from a higher dose, this approval creates a new option. What it does not create, automatically, is insurance coverage for it.

Every insurer will make its own formulary decision about whether to cover Wegovy HD, at what tier, and under what prior authorization criteria. Some plans will update their GLP-1 policies to include the higher dose, but they may require a new prior authorization submission even if your current 2.4 mg dose is already approved. A prior authorization approved for one dose of a medication does not automatically extend to a different dose, even of the same drug.

If your physician recommends moving to the 7.2 mg dose, ask the prescriber's office to initiate a new prior authorization with the clinical documentation clearly explaining why the higher dose is medically appropriate for you specifically. The stronger the documentation at the initial submission, the less likely you are to face a denial that requires an appeal.

What This Means If You Have Been Trying to Get Coverage

If you have been seeking coverage for any semaglutide-based GLP-1 medication, including the existing Wegovy doses, the landscape around these drugs continues to shift quickly.

The FDA now recognizes multiple GLP-1 treatment options in both injectable and oral form. The arrival of oral alternatives, including Foundayo (orforglipron) approved April 1, 2026, and the oral Wegovy pill approved in December 2025, has given insurers additional formulary leverage. Some plans will begin requiring patients to try an oral option before approving the more expensive injectable versions, a step therapy approach.

If you receive a denial for an injectable GLP-1 on step therapy grounds, you have the right to appeal. Ask your physician to document specifically why the injectable formulation is medically appropriate for you, including any clinical reasons why an oral alternative may not be. Step therapy exceptions are available in most states when medical necessity for the specific formulation is established.

A Note on Compounded Semaglutide

The FDA's actions in early 2026 have accelerated the timeline for removing compounded semaglutide from the market. If you have been using a compounded version through a telehealth company, you will likely need to transition to an FDA-approved branded product soon.

That transition will require navigating your insurer's prior authorization process. Starting that process now, before a supply disruption, gives you more time to appeal if your initial request is denied.

What to Do Now

If you are currently on Wegovy and interested in the higher dose: Talk to your prescriber. If they recommend Wegovy HD, ask the office to submit a new prior authorization before you expect to need the higher dose. Insurance review takes time.

If you are newly seeking coverage for any GLP-1 injectable: Ask your physician's office to submit prior authorization with complete clinical documentation, including your weight history, any weight-related conditions such as hypertension, sleep apnea, or type 2 diabetes, and any prior treatments tried. Thin submissions generate thin denials.

If you are denied: The appeal window on most initial denials is 30 to 180 days depending on your plan. Check your Explanation of Benefits for the specific deadline. A denial for a GLP-1 with complete clinical documentation behind it is frequently overturned on appeal.

Sources: